| 主权项 |
1. A method for ameliorating or treating a paramyxovirus virus infection comprising administering to a subject infected with the paramyxovirus virus an effective amount of a combination of Compound (A) and one or more of Compound (B), or a pharmaceutical acceptable salt of any of the foregoing, wherein:
the Compound (A) has the structure: wherein: R1 is selected from the group consisting of H, an optionally substituted acyl, an optionally substituted O-linked amino acid and R2 is chloro or azido; R3 is selected from the group consisting of OH, —OC(═O)RA1 and an optionally substituted O-linked amino acid; R4 and R5 are independently H or D; R6 and R7 is independently absent, H, RA1 is an optionally substituted C1-24 alkyl; RA2 is independently selected from the group consisting of H, an optionally substituted C1-24 alkyl, an optionally substituted aryl, an optionally substituted —O—C1-24 alkyl, an optionally substituted —O-aryl, an optionally substituted —O-heteroaryl, an optionally substituted —O-monocyclic heterocyclyl, RA3 is selected from the group consisting of H, an optionally substituted C1-24 alkyl and an optionally substituted aryl; RC1 and RC2 are independently selected from the group consisting of H, an optionally substituted C1-24 alkyl and an optionally substituted aryl; s is 0, 1, 2 or 3; t is 0 or 1; and Z1 is O or S; one or more of Compound (B) is selected from the group consisting of an anti-RSV antibody, a fusion protein inhibitor, an N-protein inhibitor, a RSV polymerase inhibitor, an IMPDH inhibitor, an interferon and an other compound that inhibits the RSV virus, or a pharmaceutically acceptable salt of any of the foregoing; and the paramyxovirus virus infection is selected from the group consisting of a respiratory syncytial virus infection, a parainfluenza virus infection and a metapneumovirus infection. |
